294 related articles for article (PubMed ID: 23121670)
1. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
Manzur S; Cohen S; Haimovich J; Hollander N
Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
Smith MR; Jin F; Joshi I
Mol Cancer Ther; 2004 Dec; 3(12):1693-9. PubMed ID: 15634664
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
6. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
7. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
Smith MR; Joshi I; Jin F; Obasaju C
BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
9. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
[TBL] [Abstract][Full Text] [Related]
10. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
11. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies.
Li M; Yan Z; Han W; Zhang Y
Cell Immunol; 2006 Feb; 239(2):136-43. PubMed ID: 16814270
[TBL] [Abstract][Full Text] [Related]
12. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab.
Dillman RO
Semin Oncol; 2003 Aug; 30(4):434-47. PubMed ID: 12939712
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Tobinai K
Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
16. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
Duman BB; Sahin B; Ergin M; Guvenc B
Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.
Ai L; Ren H; Shi Y; Dong Y
Int J Hematol; 2008 Jun; 87(5):459-466. PubMed ID: 18414983
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
Ansell SM; Witzig TE; Kurtin PJ; Sloan JA; Jelinek DF; Howell KG; Markovic SN; Habermann TM; Klee GG; Atherton PJ; Erlichman C
Blood; 2002 Jan; 99(1):67-74. PubMed ID: 11756154
[TBL] [Abstract][Full Text] [Related]
19. Overview of antibody therapy in B-cell non-Hodgkin's lymphoma.
Wannesson L; Ghielmini M
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S5-12. PubMed ID: 14556670
[TBL] [Abstract][Full Text] [Related]
20. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
